FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317838235> ?p ?o ?g. }

• W4317838235 endingPage "1493" @default.
• W4317838235 startingPage "1474" @default.
• W4317838235 abstract "Nintedanib is recommended for the treatment of idiopathic pulmonary fibrosis (IPF); however, treatment discontinuation due to adverse events (AEs) is common. A large-scale post-marketing surveillance study is investigating the real-world tolerability/safety of nintedanib in Japanese patients with IPF in routine clinical practice. Here, we report a 12-month interim analysis of this study.The study included Japanese patients with IPF who started nintedanib between 31 August 2015 and 25 December 2018. The primary outcome was the frequency of adverse drug reactions (ADRs), defined as AEs for which a causal relationship with nintedanib could not be excluded. The secondary outcome was change from baseline in forced vital capacity (FVC). Outcomes were analysed in patients who stopped ('discontinued' subgroup) and continued ('continued' subgroup) nintedanib after 12 months. A multivariate analysis was performed to determine potential risk factors for treatment discontinuation.Of 5578 patients in the safety analysis set, 2795 (50.1%) discontinued nintedanib within 12 months of treatment initiation. Overall, 3767 patients (67.5%) had ADRs, with 1356 (24.3%) discontinuing nintedanib because of an ADR. Among patients in the 'discontinued' subgroup (n = 2795), 1442 (51.6%) discontinued because of an ADR. The most common ADRs causing discontinuation within 3 and 12 months were hepatic function abnormal (n = 137/730; 18.8%) and diarrhoea (n = 190/1442; 13.2%), respectively. At 12 months, the decrease in FVC from baseline was smaller in the 'continued' versus the 'discontinued' subgroup (adjusted mean ± standard error change - 104.4 ± 10.9 ml vs. - 311.2 ± 29.2 ml). Stage III/IV IPF and FVC < 70% predicted at baseline were risk factors for early treatment discontinuation.About 50% of Japanese patients with IPF discontinued nintedanib within the first year of treatment, with worse lung function being associated with an increased risk of early treatment discontinuation.ClinicalTrials.gov: NCT02607722; European Union electronic register of Post-Authorisation Studies: EUPAS10891." @default.
• W4317838235 created "2023-01-24" @default.
• W4317838235 creator A5002422862 @default.
• W4317838235 creator A5004532315 @default.
• W4317838235 creator A5013199621 @default.
• W4317838235 creator A5025872899 @default.
• W4317838235 creator A5036317882 @default.
• W4317838235 creator A5053644656 @default.
• W4317838235 creator A5061852723 @default.
• W4317838235 creator A5079618433 @default.
• W4317838235 creator A5084744867 @default.
• W4317838235 date "2023-01-24" @default.
• W4317838235 modified "2023-10-05" @default.
• W4317838235 title "Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan" @default.
• W4317838235 cites W1971419861 @default.
• W4317838235 cites W2125553008 @default.
• W4317838235 cites W2138871107 @default.
• W4317838235 cites W2272059546 @default.
• W4317838235 cites W2440054067 @default.
• W4317838235 cites W2507379588 @default.
• W4317838235 cites W2515189678 @default.
• W4317838235 cites W2561968191 @default.
• W4317838235 cites W2597638604 @default.
• W4317838235 cites W2753475654 @default.
• W4317838235 cites W2766726468 @default.
• W4317838235 cites W2790223305 @default.
• W4317838235 cites W2803461852 @default.
• W4317838235 cites W2889197569 @default.
• W4317838235 cites W2889828413 @default.
• W4317838235 cites W2895854040 @default.
• W4317838235 cites W2904388381 @default.
• W4317838235 cites W2913878462 @default.
• W4317838235 cites W2923176155 @default.
• W4317838235 cites W2945205783 @default.
• W4317838235 cites W2963389474 @default.
• W4317838235 cites W3003269956 @default.
• W4317838235 cites W3031644726 @default.
• W4317838235 cites W3083433731 @default.
• W4317838235 cites W3123866413 @default.
• W4317838235 cites W3139014258 @default.
• W4317838235 cites W3166857906 @default.
• W4317838235 cites W3183909178 @default.
• W4317838235 cites W4210911278 @default.
• W4317838235 doi "https://doi.org/10.1007/s12325-022-02411-y" @default.
• W4317838235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36692681" @default.
• W4317838235 hasPublicationYear "2023" @default.
• W4317838235 type Work @default.
• W4317838235 citedByCount "2" @default.
• W4317838235 countsByYear W43178382352023 @default.
• W4317838235 crossrefType "journal-article" @default.
• W4317838235 hasAuthorship W4317838235A5002422862 @default.
• W4317838235 hasAuthorship W4317838235A5004532315 @default.
• W4317838235 hasAuthorship W4317838235A5013199621 @default.
• W4317838235 hasAuthorship W4317838235A5025872899 @default.
• W4317838235 hasAuthorship W4317838235A5036317882 @default.
• W4317838235 hasAuthorship W4317838235A5053644656 @default.
• W4317838235 hasAuthorship W4317838235A5061852723 @default.
• W4317838235 hasAuthorship W4317838235A5079618433 @default.
• W4317838235 hasAuthorship W4317838235A5084744867 @default.
• W4317838235 hasBestOaLocation W43178382351 @default.
• W4317838235 hasConcept C126322002 @default.
• W4317838235 hasConcept C165637977 @default.
• W4317838235 hasConcept C187960798 @default.
• W4317838235 hasConcept C197934379 @default.
• W4317838235 hasConcept C2777714996 @default.
• W4317838235 hasConcept C2778341716 @default.
• W4317838235 hasConcept C2778375690 @default.
• W4317838235 hasConcept C2778715236 @default.
• W4317838235 hasConcept C2780171596 @default.
• W4317838235 hasConcept C3018587741 @default.
• W4317838235 hasConcept C44249647 @default.
• W4317838235 hasConcept C535046627 @default.
• W4317838235 hasConcept C55520419 @default.
• W4317838235 hasConcept C61943457 @default.
• W4317838235 hasConcept C71924100 @default.
• W4317838235 hasConceptScore W4317838235C126322002 @default.
• W4317838235 hasConceptScore W4317838235C165637977 @default.
• W4317838235 hasConceptScore W4317838235C187960798 @default.
• W4317838235 hasConceptScore W4317838235C197934379 @default.
• W4317838235 hasConceptScore W4317838235C2777714996 @default.
• W4317838235 hasConceptScore W4317838235C2778341716 @default.
• W4317838235 hasConceptScore W4317838235C2778375690 @default.
• W4317838235 hasConceptScore W4317838235C2778715236 @default.
• W4317838235 hasConceptScore W4317838235C2780171596 @default.
• W4317838235 hasConceptScore W4317838235C3018587741 @default.
• W4317838235 hasConceptScore W4317838235C44249647 @default.
• W4317838235 hasConceptScore W4317838235C535046627 @default.
• W4317838235 hasConceptScore W4317838235C55520419 @default.
• W4317838235 hasConceptScore W4317838235C61943457 @default.
• W4317838235 hasConceptScore W4317838235C71924100 @default.
• W4317838235 hasFunder F4320310441 @default.
• W4317838235 hasIssue "4" @default.
• W4317838235 hasLocation W43178382351 @default.
• W4317838235 hasLocation W43178382352 @default.
• W4317838235 hasLocation W43178382353 @default.
• W4317838235 hasOpenAccess W4317838235 @default.
• W4317838235 hasPrimaryLocation W43178382351 @default.
• W4317838235 hasRelatedWork W2106320546 @default.

• next